On Invalid Date, Poseida Therapeutics (NASDAQ: PSTX) reported Q2 2024 earnings per share (EPS) of -$0.32, up 0% year over year. Total Poseida Therapeutics earnings for the quarter were -$31.37 million. In the same quarter last year, Poseida Therapeutics's earnings per share (EPS) was -$0.32.
As of Q3 2024, Poseida Therapeutics's earnings has grown year over year. Poseida Therapeutics's earnings in the past year totalled -$112.77 million.
What is PSTX's earnings date?
Poseida Therapeutics's earnings date is Invalid Date. Add PSTX to your watchlist to be reminded of PSTX's next earnings announcement.
What was PSTX's revenue last quarter?
On Invalid Date, Poseida Therapeutics (NASDAQ: PSTX) reported Q2 2024 revenue of $25.97 million up 29.78% year over year. In the same quarter last year, Poseida Therapeutics's revenue was $20.01 million.
What was PSTX's revenue growth in the past year?
As of Q3 2024, Poseida Therapeutics's revenue has grown -43.55% year over year. This is 120.44 percentage points lower than the US Biotechnology industry revenue growth rate of 76.88%. Poseida Therapeutics's revenue in the past year totalled $88.46 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.